Literature DB >> 34816411

Vaccines Against Vector-Borne Diseases.

Chrysoula Kitsou1, Utpal Pal2.   

Abstract

Arthropod vectors account for a number of animal and human diseases, posing substantial threats to health and safety on a global scale. Ticks are considered as one of the most prominent vectors, as they can parasitize almost any vertebrate class and transmit a multitude of infectious diseases, particularly ones that affect humans and domestic animals. While various tick species elicit different tick-borne infections in specific geographic regions, single species can have widespread effects, such as blacklegged ticks, which are widely distributed across the eastern United States and can transmit a variety of infections, including Lyme borreliosis, anaplasmosis, relapsing fever disease, ehrlichiosis, babesiosis, and Powassan virus disease. Despite increasing awareness about ticks as serious disease vectors, effective vaccines against most tick-borne infections are not available. Previously, the successful development of an anti-tick vaccine for use in veterinary animals was based on an 86-kDa midgut antigen from Rhipicephalus (formerly Boophilus) microplus ticks. Herein we describe the fundamentals of vaccine development using protein antigens as model vaccinogen candidates, beginning with the cloning, expression, and purification of recombinant proteins, host immunization, and the assessment of protective efficacy in laboratory settings using a tick-borne murine model of Lyme borreliosis.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anti-tick vaccines; Bm86; Gut antigens; Murine models; Vector-borne diseases

Mesh:

Substances:

Year:  2022        PMID: 34816411     DOI: 10.1007/978-1-0716-1888-2_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Vaccines for tick-borne diseases and cost-effectiveness of vaccination: a public health challenge to reduce the diseases' burden.

Authors:  Renata Šmit; Maarten J Postma
Journal:  Expert Rev Vaccines       Date:  2015-11-11       Impact factor: 5.217

2.  Borrelia burgdorferi BBA52 is a potential target for transmission blocking Lyme disease vaccine.

Authors:  Manish Kumar; Simarjot Kaur; Toru Kariu; Xiuli Yang; Ioannis Bossis; John F Anderson; Utpal Pal
Journal:  Vaccine       Date:  2011-09-21       Impact factor: 3.641

Review 3.  Ticks and tickborne bacterial diseases in humans: an emerging infectious threat.

Authors:  P Parola; D Raoult
Journal:  Clin Infect Dis       Date:  2001-03-14       Impact factor: 9.079

4.  Developing Anti-tick Vaccines.

Authors:  Alina Rodríguez-Mallon
Journal:  Methods Mol Biol       Date:  2016

5.  Vaccination of cattle with TickGARD induces cross-reactive antibodies binding to conserved linear peptides of Bm86 homologues in Boophilus decoloratus.

Authors:  David Odongo; Lucy Kamau; Robert Skilton; Stephen Mwaura; Cordula Nitsch; Anthony Musoke; Evans Taracha; Claudia Daubenberger; Richard Bishop
Journal:  Vaccine       Date:  2006-10-11       Impact factor: 3.641

6.  A Borrelia burgdorferi Surface-Exposed Transmembrane Protein Lacking Detectable Immune Responses Supports Pathogen Persistence and Constitutes a Vaccine Target.

Authors:  Faith Kung; Simarjot Kaur; Alexis A Smith; Xiuli Yang; Cara N Wilder; Kavita Sharma; Ozlem Buyuktanir; Utpal Pal
Journal:  J Infect Dis       Date:  2016-01-07       Impact factor: 5.226

7.  ANTIDotE: anti-tick vaccines to prevent tick-borne diseases in Europe.

Authors:  Hein Sprong; Jos Trentelman; Ingar Seemann; Libor Grubhoffer; Ryan O M Rego; Ondřej Hajdušek; Petr Kopáček; Radek Šíma; Ard M Nijhof; Juan Anguita; Peter Winter; Bjorn Rotter; Sabina Havlíková; Boris Klempa; Theo P Schetters; Joppe W R Hovius
Journal:  Parasit Vectors       Date:  2014-02-21       Impact factor: 3.876

  7 in total
  1 in total

1.  Immunoinformatics-Based Proteome Mining to Develop a Next-Generation Vaccine Design against Borrelia burgdorferi: The Cause of Lyme Borreliosis.

Authors:  Kashaf Khalid; Omar Ahsan; Tanwir Khaliq; Khalid Muhammad; Yasir Waheed
Journal:  Vaccines (Basel)       Date:  2022-08-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.